All In Biotech

Drug Trial Radar · NCT01724866

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen

Last checked: Nov 20, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Mar 25, 2013

Primary completion

Aug 12, 2014

Study completion Aug 12, 2014

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Nov 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of test doses of SPI-2012 on the duration of severe neutropenia (DSN) during Cycle 1 in participants with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy.

Conditions

  • Neutropenia

Interventions

  • SPI-2012Drug

    SPI-2012 SC injection.

  • PegfilgrastimDrug

    Pegfilgrastim SC injection, per manufacturer's Prescribing Information.

  • DocetaxelDrug

    Docetaxel given based on standard dose for chemotherapy.

  • CyclophosphamideDrug

    Cyclophosphamide given based on standard dose for chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Neutropenia (DSN) in Cycle 1Time frame: Cycle 1 (each cycle was 21 days)

Locations

27 sites in 6 countries. Site status is shown where the registry gives one.

  • Arizona Center for Cancer Care

    Glendale, Arizona

  • Desert Springs Cancer Care

    Scottsdale, Arizona

  • California Cancer Associates for Research and Excellence

    Fresno, California

  • Beaver Medical Group

    Highland, California

  • California Cancer Associates for Research and Excellence

    Los Angeles, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Kentucky Cancer Clinic

    Hazard, Kentucky

  • New York Oncology Hematology, PC

    Albany, New York

  • North Shore Hematology/Oncology Associates

    Setauket, New York

  • Good Samaritan Hospital, Corvallis

    Corvallis, Oregon

  • Royal Hobart

    Brisbane, Australia

  • Ashford Cancer Center Research

    Kurralta Park, Australia

  • Breast Cancer Research Center, WA

    Perth, Australia

  • Ballarat Oncology & Haematology

    Wendouree, Australia

  • Frankston Hospital

    Frankston, Victoria, Australia

  • LTD " Cancer Center of Adjara Autonomic Republic"

    Batumi, Georgia

  • Ltd ' Medulla - Chemotherapy and Immunotherapy Clinic

    Tbilisi, Georgia

  • State Health Center

    Budapest, Hungary

  • National Institute of Oncology

    Budapest, Hungary

  • Uzsoki Hospital

    Budapest, Hungary

  • University Debrecen, Oncology Clinic

    Debrecen, Hungary

  • Szabolcs - Szatmár - Bereg megyei Kórházak és Egyetemi Oktatókórház

    Nyíregyháza, Hungary

  • Ziv Medical Center

    Safed, Israel

  • Regionalny Szpital Specjalistyczny

    Grudziądz, Poland

  • Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Dzienny Oddział Chemioterapii

    Racibórz, Poland

  • MTZ Clinical Research Sp. z o.o.

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.